MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · Essen University Hospital · +13 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
643
total citations
- FWCI
- 46.22
- Percentile
- 100%
- References
- 39
Citations per year
Authors
15- PAPaolo A. Ascierto
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
- DSDirk Schadendorf
Essen University Hospital
- CBCarola Berking
Ludwig-Maximilians-Universität München
- SSSanjiv S. Agarwala
St. Luke's University Health Network, Temple University
- CMCarla M.L. van Herpen
Radboud University Medical Center, Radboud University Nijmegen
Topics & keywords
Topics
Keywords
- Neuroblastoma RAS viral oncogene homolog
- Medicine
- Melanoma
- Internal medicine
- MEK inhibitor
- Oncology
- Clinical endpoint
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.